Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2014
03/13/2014US20140072576 Chemokine receptor antagonists and use thereof
03/13/2014US20140072564 Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
03/13/2014US20140072555 Inhibitor Compounds and Cancer Treatment Methods
03/13/2014US20140072554 Pyrazolo[1,5-a]pyrimidines for antiviral treatment
03/13/2014US20140072540 Compositions and methods for the treatment of krabbe and other neurodegenerative diseases
03/13/2014US20140072536 Methods of treating muscular dystrophy
03/13/2014US20140072534 Novel therapy for multiple sclerosis using vitamin d and gut bacteria
03/13/2014US20140072532 Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
03/13/2014US20140072531 Method for preparing microparticles with reduced initial burst and microparticles prepared thereby
03/13/2014US20140072529 Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
03/13/2014US20140072526 Method for the production of adsorbates of a rasagiline salt having a water-soluble adjuvant
03/13/2014US20140070446 Sustained-release solid preparation for oral use
03/13/2014US20140069419 Isoxazolidine derivatives
03/13/2014DE102012018115A1 New aryl-N-(arylalkyl) carbamate compounds, used to prepare pharmaceutical composition for prophylactic and/or therapeutic treatment of diseases including e.g. acute and chronic neurogenic pain, and neurological and psychiatric diseases
03/13/2014DE102010062810B4 2-(R2-Thio)-10-[3-(4-R1-piperazin-1-yl)propyl]-10H-phenothiazine zur Behandlung neurodegenerativer Erkrankungen ausgewählt aus beta-Amyloidopathien und alpha-Synucleinopathien 2- (R2-thio) -10- [3- (4-R1-piperazin-1-yl) propyl] -10H-phenothiazine for the treatment of neurodegenerative diseases selected from beta-Amyloidopathien and alpha-synucleinopathies
03/13/2014CA2877184A1 Lpar-substituted cyanopyrazole compounds
03/12/2014EP2706062A2 Novel cephalosporin derivative and pharmaceutical composition thereof
03/12/2014EP2706059A1 Diazacarbazoles and methods of use
03/12/2014EP2705855A1 Photodynamic therapy or diagnostic agent, using infrared-spectrum light
03/12/2014EP2705854A1 Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
03/12/2014EP2705849A2 A preparation for use of aspartate for regulating glucose levels in blood
03/12/2014EP2705847A1 Composition for treating psoriasis
03/12/2014EP2705846A2 Methods for reducing allergies caused by environmental allergens
03/12/2014EP2705845A1 Combination of zinc salt and anti-h pilori agent as fast acting inhibitor of gastric acid secretion
03/12/2014EP2705844A1 Nutritional composition
03/12/2014EP2705843A1 Therapeutic approaches for treating epilepsy and related disorders through reduction of epileptogenesis
03/12/2014EP2705842A1 Therapeutic approaches for treating parkinson's disease
03/12/2014EP2705841A1 Combinations of nootropic agents for treating cognitive dysfunctions
03/12/2014EP2705840A1 Use of rifapentine in the treatment and/or prevention of active tuberculosis disease
03/12/2014EP2705839A1 Pharmaceutical composition comprising lacidipine and process of preparation
03/12/2014EP2705838A1 Tiotropium preparations
03/12/2014EP2705837A1 Diclofenac Formulation
03/12/2014EP2705836A1 Pharmaceutical compositions having desirable bioavailability
03/12/2014EP2705763A1 Method for utilizing extraction residue of yeast extract
03/12/2014EP2705761A1 Nutritional composition for pregnant women
03/12/2014EP2705753A1 2-Phenyl-imidazolotriazinone compounds as PDE5 inhibitors
03/12/2014EP2705181A1 Combination pharmaceutical compositions and uses thereof
03/12/2014EP2705151A2 Selective reduction of the deleterious activity of extended tri-nucleotide repeat containing genes
03/12/2014EP2705047A1 Bioactive fractions and compounds from dalbergia sissoo for the prevention or treatment of osteo-health related disorders
03/12/2014EP2705044A1 Novel cephalosporins useful as antibacterial agents
03/12/2014EP2705042A1 Rifaximin dimethylformamide solvate
03/12/2014EP2705041A1 Crystalline salts of asenapine
03/12/2014EP2705039A2 Bromodomain inhibitors and uses thereof
03/12/2014EP2705038A1 Substituted imidazopyridines and the use thereof
03/12/2014EP2705037A1 Substituted imidazopyridines and imidazopyridazines and the use thereof
03/12/2014EP2705036A1 Tricyclic sulfonamide compounds and methods of making and using same
03/12/2014EP2705035A1 Tricyclic pyrazole sulfonamide compounds and methods of making and using same
03/12/2014EP2705034A1 Crystalline sodium salt of an hiv integrase inhibitor
03/12/2014EP2705033A1 Isoindolinone derivatives
03/12/2014EP2705032A1 Dihydroquinoline derivatives as bromodomain inhibitors
03/12/2014EP2705030A1 Partially saturated tricyclic compounds and methods of making and using same
03/12/2014EP2705029A1 Novel compounds as modulators of protein kinases
03/12/2014EP2705027A1 Amorphous solid salts
03/12/2014EP2705025A1 Hydroxymethyl biaryl benzotriazole derivatives
03/12/2014EP2705013A1 Pentylenetetrazole derivatives
03/12/2014EP2705012A1 Radiolabeled amino acids for diagnostic imaging
03/12/2014EP2704750A2 Tolerogenic synthetic nanocarriers for antigen-specific deletion of t effector cells
03/12/2014EP2704748A1 Bis-(alpha-amino-diol-diester) containing polyesteramide for ophtamology
03/12/2014EP2704747A1 Eye drops for treatment of conjunctivochalasis
03/12/2014EP2704734A1 Composition useful for the treatment of lipid metabolism disorders
03/12/2014EP2704727A2 Skin and hair regeneration using polysaccharide-based hydrogels
03/12/2014EP2704726A2 Proton-motive force stimulation to potentiate aminoglycoside antibiotics against persistent bacteria
03/12/2014EP2704725A1 Boiled sugar sweet comprising non-fructosylated -galactooligosaccharides
03/12/2014EP2704724A1 Improved suspension formulation of a corticosteroid for administration by inhalation
03/12/2014EP2704723A2 Treatment of polycystic disease
03/12/2014EP2704722A1 Multiple myeloma treatment
03/12/2014EP2704721A1 Pyruvate kinase activators for use in therapy
03/12/2014EP2704720A1 Pyruvate kinase activators for use in therapy
03/12/2014EP2704719A1 Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
03/12/2014EP2704718A1 Methods for detecting enhanced risk of opioid-induced hypoxia in a patient
03/12/2014EP2704717A1 Method of treating cancer and bone cancer pain
03/12/2014EP2704716A1 Katp antagonists (glibenglamid) for use for promoting growth and/or treating hyperglycaemia of a premature infant
03/12/2014EP2704715A2 Tolerogenic synthetic nanocarriers for generating cd8+regulatory t cells
03/12/2014EP2704714A2 Tolerogenic synthetic nanocarriers to reduce cytotoxic t lymphocyte responses
03/12/2014EP2704713A1 Csf-1r inhibitors for treatment of brain tumors
03/12/2014EP2704712A1 Isoxazolines as therapeutic agents
03/12/2014EP2704711A1 Use of fk506 for the treatment of pulmonary arterial hypertension
03/12/2014EP2704710A1 A composition for treating autoimmune disorders and methods thereof
03/12/2014EP2704709A1 Macrocyclic lactones and use thereof
03/12/2014EP2704708A1 Compounds for use in the treatment of filariasis
03/12/2014EP2704707A1 Novel benzofurane-piperidine compounds
03/12/2014EP2704706A1 Composition comprising angiotensin ii receptor antagonist and antioxidant for maintaining and/or improving skin properties
03/12/2014EP2704705A1 Use of bethanechol for treatment of xerostomia
03/12/2014EP2704704A1 Probiotic bacteria for the topical treatment of skin disorders
03/12/2014EP2704703A1 Transdermal compositions of ibuprofen and methods of use thereof
03/12/2014EP2704702A2 Composition and method for treatment of diabetes
03/12/2014EP2704701A1 Compounds for inflammation and immune-related uses
03/12/2014EP2704700A1 Selecting use of proteasome inhibitors based on nf-kb2 sequence
03/12/2014EP2704699A1 Methods for treating prostate cancer
03/12/2014EP2704697A1 Sustained release paracetamol formulations
03/12/2014EP2704696A1 Taste-masked ibuprofen granules
03/12/2014EP2704693A1 Controlled release of immunosuppressants from synthetic nanocarriers
03/12/2014EP2704688A1 Cochleate compositions and methods of making and using same
03/12/2014EP2704687A1 A topical formulation comprising a corticosteroid as active ingredient
03/12/2014EP2704596A1 Oral compositions comprising creatine
03/12/2014EP2704592A1 Food product comprising rye
03/12/2014EP2704574A1 Cyclohexene benzotriazole derivatives
03/12/2014EP2704573A1 Aminomethyl biaryl benzotriazole derivatives
03/12/2014EP2704572A1 Compounds for inhibiting cell proliferation in egfr-driven cancers
03/12/2014EP2704571A1 Amino-pyridine-containing spleen tyrosine kinase (syk) inhibitors
1 ... 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 ... 7860